GlaxoSmithKline plc (LSE:GSK) announced that, following the voluntary Open Offer undertaken by its subsidiary, GlaxoSmithKline Pte Ltd, GSK has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India (GlaxoSmithKline Pharmaceuticals Limited), from 50.7% to 75%. GlaxoSmithKline Pharmaceuticals Limited will remain publicly-listed.

More than 100 countries have now approved Boehringer Ingelheim's Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition (non-valvular atrial fibrillation, nvAF).(1) The 100th approval was announced by the Jordan Food and Drug Administration. Further regulatory approvals for Pradaxa® are expected to be received in the near future.

Bristol-Myers Squibb Company today announced donations totaling $1 million in 2013 to four nonprofit organizations that support patients with cancer. The donations will fund the development and availability of educational materials for patients and caregivers about the emerging field of cancer research and treatment called immuno-oncology.

Novartis has announced additional steps to extend its leadership in clinical trial data transparency. Since 2005, and before requirements were in place, Novartis has been voluntarily disclosing summaries of Clinical Study Reports of its innovative medicines on its own website.

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) have announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

Boehringer Ingelheim Fremont Inc. received the East Bay Innovation Award in recognition for its contribution to the East Bay's culture of innovation. Boehringer Ingelheim's Fremont, California site is an arm of its biopharmaceutical division and provides the entire production technology chain from DNA to drug substance.

Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.